Examples of 'concentration-time' in a sentence
Meaning of "concentration-time"
concentration-time (noun) - a term commonly used in pharmacokinetics to describe the relationship between the concentration of a drug in the body and the time elapsed since its administration. It is important in determining the effectiveness and duration of drug action
How to use "concentration-time" in a sentence
Basic
Advanced
concentration-time
Area under concentration-time curve from zero to time t.
What criteria should be used to define an adequately characterized concentration-time profile?
Early portions of the concentration-time profile are not of clinical importance.
Non-compartmental pharmacokinetic analysis was performed on the plasma concentration-time data.
Plasma concentration-time data were analyzed for rosiglitazone and metformin.
Compartmental methods estimate the concentration-time graph using kinetic models.
Plasma concentration-time data and pharmacokinetic parameters were summarized by treatment.
Pharmacokinetic parameter values were evaluated from concentration-time profiles by noncompartmental methods.
Sample concentration-time profiles that should be given for each subject.
The pharmacokinetic parameters determined from the concentration-time data of asimadoline are,.
A full plasma concentration-time profile was obtained from each animal.
Cmax and tmax were to be taken directly from the observed concentration-time data.
All plasma concentration-time profiles were analysed pharmacokinetically by a non-compartmental analysis.
Cmax and the area under the plasma concentration-time curve were dose proportional.
A concentration-time curve was constructed for each volunteer for each period.
See also
concentration-response curve
concentration-response curves
concentrations
concentrations are expressed
concentration-response curves
concentrations
concentrations are expressed
Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
The concentration-time profile following intravenous administration is well described by a twocompartment model.
Additional measured parameters could include compartmental analysis of concentration-time data obtained following i . v.
Individual plasma concentration-time profiles were subjected to a non-compartmental pharmacokinetic analysis.
The following pharmacokinetic parameters were determined from the plasma drug concentration-time data.
Daratumumab concentration-time profiles were similar following the monotherapy and combination therapies.
The pharmacokinetic parameters were determined from mean concentration-time data in the test subjects.
The concentration-time profile following intravenous administration is well described by a two - compartment model.
Following the measurement of plasma samples and dosing solutions, plasma concentration-time curve is plotted.
The concentration-time profile of docetaxel was consistent with a three-compartment pharmacokinetic model.
The in vitro metabolic half-life was determined from the concentration-time plots using WinNonlin.
The plasma concentration-time profile of intravenously administered gadofosveset conforms to a twocompartment open model.
Pharmacokinetic parameters of a test compound are determined from the plasma concentration-time data using non-compartmental methods.
The total drug concentration-time profiles were biphasic and were fitted to a linear two compartment model.
AUC is the área under the plasma concentration-time curve.
The area under the plasma concentration-time curve increases with repeated administration of esomeprazole.
Cmax and Tmax were reported directly from the concentration-time data.
The plasma concentration-time profile of intravenously administered gadofosveset conforms to a two - compartment open model.
NCA was performed using the individual plasma concentration-time profiles from each animal.
Serum concentration-time profiles of ustekinumab were generally predictable after single or multiple subcutaneous dose administrations.
The mean total ceftriaxone plasma concentration-time profile for each dose is shown in Figure 2.
Standard noncompartmental pharmacokinetic parameters were derived from the individual plasma concentration-time profiles using WinNonlin Pro.
The insulin concentration-time profiles after each cycle of dosing were compared for each treatment group.
Blood samples were collected to adequately cover the full plasma concentration-time profile of the API.
The serum concentration-time profiles were used to determine PK parameters.
Figure 2 presents schematic graphs showing examples of modified concentration-time PK profiles of a single dose unit.
The serum concentration-time data were used to determine PK parameters.
Panel C of Figure 2 provides another example of a dose unit having a modified concentration-time PK profile.
The drug concentration-time profiles of timolol in cornea is shown in Fig.
Fig . 9 demonstrates the mean plasma concentration-time profiles achieved.
The drug concentration-time profiles of timolol in iris-ciliary body is shown in Fig.
PK Profiles Mean aripiprazole rats ' serum concentration-time profiles are shown graphically in FIG.
Plasma concentration-time curves of penciclovir are similar following single and repeat t.l.d.
Figure 14 graphically depicts plasma concentration-time curves of decitabine in non-human primates.
Input data were dose-normalized group arithmetic mean concentration-time data.
